Expertise in
4
conditions

Dr. Antoni Ribas

Hematology | Oncology
Office
100 UCLA Medical Plz Ste 550, 
Los Angeles, CA 
Offers Telehealth
Expertise in
4
conditions
Office
100 UCLA Medical Plz Ste 550, 
Los Angeles, CA 

Overview

Antoni Ribas is a Hematologist and an Oncologist practicing medicine in Los Angeles, California.

Dr. Ribas is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Melanoma, Melanoma of the Eye, Synovial Sarcoma, and Uveal Melanoma.

He is actively involved in clinical research, co-authoring 402 peer reviewed articles and participating in 14 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
100 UCLA Medical Plz Ste 550, Los Angeles, CA 90024
Other Locations
Office
100 Medical Plz Ste 550, Los Angeles, CA 90095

Additional Areas of Focus

Dr. Ribas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2026
Intervention Type: Biological
Study Drugs: Pembrolizumab, Talimogene Laherparepvec
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade
Enrollment Status: Completed
Publish Date: July 30, 2025
Intervention Type: Drug, Biological, Procedure, Other
Study Phase: Phase 1
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
Enrollment Status: Terminated
Publish Date: December 04, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Binimetinib, Nivolumab
Study Phase: Phase 2
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: KPT-9274, Niacin ER, Nivolumab
Study Phase: Phase 1
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: November 01, 2023
Intervention Type: Biological, Other, Drug, Procedure
Study Drugs: Aldesleukin, Busulfan, Cellular Therapy, Filgrastim, Fludarabine, Plerixafor
Study Phase: Phase 1
View 9 Less Clinical Trials

402 Total Publications

Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.
Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.
Journal: Research square
Published: August 20, 2026
Similar Doctors
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (8.5 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Referral may be required

Sandra Fallon M.D. Inc.

2020 Santa Monica Blvd Ste 580, 
Santa Monica, CA 
 (3.5 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Singh is a Hematologist and an Oncologist practicing medicine in Santa Monica, California. Dr. Singh is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Ewing Sarcoma, Tissue Biopsy, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Gottfried E. Konecny
Hematology | Oncology
Expertise in
13
conditions
Dr. Gottfried E. Konecny
Hematology | Oncology
Referral may be required

Office

100 Medical Plz Ste 550, 
Los Angeles, CA 
 (0.6 miles away)
310-794-4955
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gottfried Konecny is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Konecny is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor.

Frequently Asked Questions about Dr. Antoni Ribas

How do I make an appointment with Dr. Antoni Ribas?

You can book an appointment with Dr. Antoni Ribas by calling their office at 310-794-4955. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Antoni Ribas a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Antoni Ribas is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Antoni Ribas specialize in?

While Dr. Antoni Ribas is a Hematology, they have specific expertise in Melanoma, Melanoma of the Eye, and Synovial Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Antoni Ribas participate in research or clinical trials?

Yes. Dr. Antoni Ribas has published 402 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Antoni Ribas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Antoni Ribas accept my insurance?

Dr. Antoni Ribas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-794-4955 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ribas's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile